Table 4 Adjusted hazard ratios and 95% confidence intervals of post-treatment predictors for HCC, stratified by treatment response.
Predictors | Patients with SVR | Patients with NSVR | ||
|---|---|---|---|---|
Total (95% CI) | Non-cirrhosis (95% CI) | Total (95% CI) | Non-cirrhosis (95% CI) | |
Age | 1.08 (1.05–1.11) | 1.1 (1.06–1.14) | 1.07 (1.02–1.13) | 1.06 (1.00–1.13) |
Gender | ||||
Female | 1.00 | 1.00 | 1.00 | 1.00 |
Male | 1.63 (1.03–2.58) | 1.91 (1.04–3.51) | 1.36 (0.61–3.03) | 0.91 (0.29–2.83) |
Serum levels of ALT (U/L) | ||||
<45 | 1.00 | 1.00 | ||
≥45 | 0.97 (0.45–2.1) | 1.52 (0.52–4.47) | ||
Serum levels of AST (U/L) | ||||
<45 | 1.00 | 1.00 | 1.00 | 1.00 |
≥45 | 2.47 (1.23–4.98) | 1.79 (0.57–5.6) | 6.20 (1.78–21.53) | 4.11 (1.11–15.17) |
Cirrhosis | ||||
No | 1.00 | — | 1.00 | |
Yes | 2.14 (1.30–3.53) | — | 1.01 (0.42–2.44) | |
Platelet count (103/uL) | ||||
≥200 | 1.00 | 1.00 | 1.00 | |
100–200 | 1.30 (0.68–2.49) | 1.54 (0.70–3.39) | 1.00 | |
<100 | 2.19 (1.00–4.82) | 1.92 (0.62–5.99) | 5.52 (2.24–13.59) | |
P for trend | 0.0479 | 0.2225 | ||
Alpha fetoprotein (ng/mL) | ||||
<5 | 1.00 | 1.00 | ||
5–10 | 1.25 (0.72–2.15) | 1.35 (0.67–2.72) | ||
10–20 | 2.42 (1.16–5.08) | 4.16 (1.45–11.97) | ||
≥20 | 9.58 (3.15–29.14) | 8.54 (1.13–64.49) | ||
P for trend | 0.0011 | 0.0053 | ||
